Surgenex
- Company typePrivate
- Founded2014
- HeadquartersScottsdale, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Surgenex firmographics
Firmographics- Name
- Surgenex
- Legal name
- Surgenex LLC
- Website
- https://surgenex.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Surgenex industry classification
Industry- Product category
- Allograft Tissue Products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836), Ophthalmic Goods (3851)
- akta.pro primary industry
- Acellular/Decellularized Matrices & ECM Products (HLAAAGAF)
- akta.pro secondary industries
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)
Keywords
Where Surgenex is headquartered
LocationHeadquarters
- HQ city
- Scottsdale
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Surgenex business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Others
Revenue model
- Allograft Tissue Products: Sale of human cellular and tissue-based products including placental-derived allografts (AmnioGraft, SurGraft series), chorion-derived products (ArdeoGraft series), bone matrix implants (SurMatrix DBM products), and structural/tendon allografts. Products sold with various HCPCS codes for reimbursement.
- Contract Manufacturing & Research Services: Partnering with other organizations for distribution of Surgenex branded allografts, private label of established technology, technology transfer and custom processing, and full product and process development from concept to commercialization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | ArdeoGraft - HCPCS Code Q4333 |
| Unit Pricing | Pay-as-you-go | PelloGraft - HCPCS Code Q4320 |
| Unit Pricing | Pay-as-you-go | RenoGraft - HCPCS Code Q4321 |
| Unit Pricing | Pay-as-you-go | VitoGraft - HCPCS Code Q4317 |
| Unit Pricing | Pay-as-you-go | SurGraft - HCPCS Code Q4209 |
| Unit Pricing | Pay-as-you-go | SurGraft AC - HCPCS Code Q4393 |
| Unit Pricing | Pay-as-you-go | SurGraft ACA - HCPCS Code Q4394 |
| Unit Pricing | Pay-as-you-go | SurGraft XT - HCPCS Code Q4269 |
| Unit Pricing | Pay-as-you-go | SurGraft FT - HCPCS Code Q4268 |
| Unit Pricing | Pay-as-you-go | SurGraft TL - HCPCS Code Q4263 |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Surgenex product offering
Product offeringCore offering
Surgenex manufactures and distributes human cellular and tissue-based allograft products, including dehydrated placental tissue allografts (ArdeoGraft, PelloGraft, RenoGraft, SanoGraft, VitoGraft, SurGraft family, SurSight), orthobiologic bone matrix implants (SurMatrix DBM putty, fibers, cancellous and cortical particulates, tendons, structural allografts), and acellular dermal matrix products. All allografts are processed using the proprietary Excellion® method at the company's Scottsdale, Arizona facility and sold to healthcare providers under HCPCS reimbursement codes.
Product overview
Surgenex is an industry leading biotechnology firm specializing in human cellular and tissue-based products, specifically placental tissue and musculoskeletal-based implants. The product portfolio consists of two main categories: Birth Tissue Allografts (placental-based products including ArdeoGraft, PelloGraft, RenoGraft, SanoGraft, VitoGraft, and the SurGraft family with variants like SurGraft AC, SurGraft ACA, SurGraft FT, SurGraft TL, and SurGraft XT, plus ocular product SurSight) and Orthobiologics/Bone Matrix products under the SurMatrix brand (including DBM Putty, Demineralized Cortical Fibers, DBM Cancellous products, Tendons, and Structural Allografts). The company also offers ArdeoGraft Surgical for surgical applications. All products are processed using the proprietary Excellion process under FDA cGTP and AATB standards.
Differentiator
Problem solved
Functional benefit
Products and services
- ArdeoGraft® Surgical Cutting-edge dual layer allograft derived from chorion, designed for both topical and surgical applications. Acts as a protective barrier offering exceptional coverage and shielding acute and chronic wounds from the surrounding environment. Intended for surgical applications.
- ArdeoGraft® Dual layer chorion-derived placental allograft designed for wound care applications. Provides a protective barrier and aids in the development of granulation tissue in acute and chronic closures.
- PelloGraft® Meticulously designed dual-layer amnion/chorion derived placental allograft. Properties of these avascular membranes provide enhanced handling. Effective as a protective covering in management of chronic non-healing ulcers including diabetic, pressure, and venous ulcers.
- RenoGraft® Triple-layer allograft comprised of amnion, chorion, and amnion layers. Meticulously designed for wound coverage using a proprietary manufacturing process, serving as a protective barrier to facilitate optimal wound care.
- SanoGraft® State-of-the-art single layer allograft derived from amnion. Serves as a protective barrier ensuring optimal protection for chronic non-healing ulcers including diabetic, pressure, and venous ulcers.
- VitoGraft®
Companies that use Surgenex
Customer profileSegments8 records
Ideal customer profiles4 records
Surgenex technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Surgenex partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Palomino GroupcoreSurgenex partnered with the Palomino Group to launch a dedicated reimbursement hotline for customers. The partnership delivers expert reimbursement support including insurance benefit verification, prior authorization, appeal support, and billing/coding services. Hotline operates 8 a.m. – 8 p.m. EDT Monday-Friday with phone (1-888-404-9398), fax (1-888-404-9384), and email ([email protected]).
- Phoenix Donor ServicescorePhoenix Donor Services is referenced as the tissue procurement partner for Surgenex. Independent, contracted tissue recovery agencies follow strict protocols in accordance with FDA regulations and AATB standards.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Surgenex competitors and assessment
Company assessmentBroad incumbents
- Arthrex: Orthopedic and sports medicine device leader with allograft tendon, bone, and orthobiologic offerings that overlap directly with Surgenex's SurMatrix Tendons, structural allografts, and DBM products for foot & ankle and sports medicine applications.
- Smith+Nephew: Global medical device company with orthobiologics, wound care, and sports medicine franchises (including legacy Osiris Therapeutics placental tissue products). Competes with Surgenex in advanced wound management and orthobiologics through deep hospital sales coverage.
- Integra LifeSciences: Larger medical device incumbent with regenerative technology and DBM/orthobiologic lines (e.g., Integra Dermal Regeneration Template, Aurora DBM) competing with Surgenex's SurMatrix orthobiologics and dermal matrix products across hospital channels.
- Medtronic: Spinal surgery market leader with Infuse (rhBMP-2) and broader bone graft substitute portfolio. Competes against Surgenex's SurMatrix DBM and laminar bone products in spinal fusion procedures.
- Stryker: Diversified orthopedic medtech incumbent with bone graft substitute, regenerative, and sports medicine offerings. Competes with Surgenex's orthobiologic line in large hospital systems where Stryker holds orthopedic contracts.
Direct peers
- Organogenesis: Public regenerative medicine company with amniotic membrane products (e.g., Apligraf, Affinity, NuShield) overlapping Surgenex's placental allograft and wound care lines. Comparable customer base across wound care, surgical, and ophthalmic applications.
- AlloSource: Nonprofit tissue bank providing birth tissue, sports medicine, and orthobiologic allografts through AATB-accredited processing. Direct overlap with Surgenex's placental membrane and musculoskeletal product portfolios.
- MTF Biologics: Nonprofit tissue bank distributing placental, dermal, and musculoskeletal allografts with comparable AATB-accredited processing standards. Competes across the same wound care, orthobiologics, and surgical reconstruction segments.
- LifeNet Health: Nonprofit tissue bank and organ procurement organization offering placental, dermal, bone, and tendon allografts. Competes in the same wound care, dental, ophthalmic, and orthopedic reconstructive segments.
- MiMedx: Direct competitor in the placental tissue allograft space with branded EpiFix and AmnioFix amniotic membrane products for wound care and surgical applications. Comparable product positioning, reimbursement model, and target customer segments (wound care centers, ASCs, hospitals).
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Surgenex social profiles
Digital presenceSurgenex compliance and trust
Trust signalCompliance7 records
Surgenex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Surgenex leadership team
Management profileNumber of profiles
Profiles3 records
Surgenex funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Surgenex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Surgenex
What does Surgenex do?
Surgenex manufactures and distributes human cellular and tissue-based allograft products, including dehydrated placental tissue allografts (ArdeoGraft, PelloGraft, RenoGraft, SanoGraft, VitoGraft, SurGraft family, SurSight), orthobiologic bone matrix implants (SurMatrix DBM putty, fibers, cancellous and cortical particulates, tendons, structural allografts), and acellular dermal matrix products. All allografts are processed using the proprietary Excellion® method at the company's Scottsdale, Arizona facility and sold to healthcare providers under HCPCS reimbursement codes.
Is Surgenex a public or private company?
Surgenex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Surgenex founded?
Surgenex was founded in 2014. It employs 11 to 50 people.
Where is Surgenex based?
Surgenex is headquartered in Scottsdale, United States, in the North America region.
How does Surgenex make money?
Two revenue lines are on record. Allograft Tissue Products are the primary driver. The others are contract Manufacturing & Research Services.
Who are Surgenex's main competitors?
Broad incumbents on record are Arthrex, Smith+Nephew, Integra LifeSciences, Medtronic and Stryker. Direct peers are Organogenesis, AlloSource, MTF Biologics, LifeNet Health and MiMedx.
Does Surgenex have an API?
No public API is recorded for Surgenex.
What industry is Surgenex in?
Surgenex's product category is Allograft Tissue Products. Its primary akta.pro industry code is HLAAAGAF, Acellular/Decellularized Matrices & ECM Products, with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 325414 and its SIC code is 3842.